The Medtech Strategist: “CorFlow Therapeutics is a Start-Up to Watch”admin
Baar, Switzerland, September 1st 2017
The MedTech Strategist has published a review article in it’s current issue of CorFlow Therapeutics AG and CorFlow’s Controlled Flow Infusion (CoFITM) technology.
Jon H. Hoem, CorFlow’s CEO and Co-Founder, said: “We are very pleased to be featured in The MedTech Strategist so early after the company foundation in 2016. The CorFlow profile highlights how important microvascular obstruction is becoming in severe heart attack patients to improve the outcome of these patients.”
The MedTech Strategist article (download the article here) explores the growing role of microvascular obstruction (MVO) in severe heart attack patients and how the CoFITM technology can help to diagnose and treat MVO. The article highlights that evidence is accumulating that microvascular obstruction is an independent predictor of a poor prognosis months and years after the heart attack. In particular, the article outlines the paradigm shift from epicardial stent placements alone to new technologies which also can improve the microcirculation after the heart attack. Even if the article admits that there are many unknowns at this early stage, it also acknowledges that CorFlow’s early mover advantage enables the company to create a valuable intellectual property position.
The CorFlow CoFITM (pronounced “coffee”) System consists of a Class IIb console and Class III rapid exchange catheter which fits the work-flow for acute heart attack patients. The devices are in non-clinical validation testing and will enter clinical trials in 2018. CorFlow is backed by private investors who over decades have invested in successful cardiovascular medical device companies. The company expects to close its Seed+ financing round later in 2017.
The MedTech Strategist is a leading publication which explores how global medical device innovation plays out in its various forms – clinical, technological, business model, marketplace, and financing. The publication is led by the co-editors-in-chief David Cassak and Stephen Levin who over decades have covered the world-wide medical device arena. In every issue The MedTech Strategist provides a wide range of articles from interviews with industry leaders to profiles of ground-breaking start-ups like CorFlow Therapeutics.
The MedTech Strategist,
Vol. 4 No. 12
In addition to featuring CorFlow Therapeutics, the following articles are provided in the latest issue:
Profile article of Intersect ENT: a company pioneering the way to implant an adjunct to sinus surgery to treat chronic sinusitis.
Market brief of the spine market which in the second quarter had a slowdown in elective procedures which can be an indication that US high-deductible insurance plans cause patients to delay non-essential care.
Veracyte: building a sustainable genomics diagnostics business.
Reimbursement challenges: how new US federal regulations can effect the reimbursement of clinical laboratory tests.
Wound care: how wound care companies developing mobile point-of-care assessment technologies can improve the care for chronic wound patients.
Other start-ups to watch: Murj (platform to manage the data generated from remotely monitored cardiac devices such as pacemakers) and Promaxo (developing an office-based detection system for prostate cancer).